ClearBridge Investments
PTGX icon

ClearBridge Investments’s Protagonist Therapeutics PTGX Stock Holding History

ClearBridge Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.5M Buy
621,820
+131,978
+27% +$11.7M 0.06% 275
2025
Q4 		$42.8M Buy
+489,842
New +$40.1M 0.03% 349

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

ClearBridge Investments's PTGX Position: Q1 2026 in Review

ClearBridge Investments increased its Protagonist Therapeutics (PTGX) stake by 27% in Q1 2026, buying an estimated $11.7M and bringing the position to 621,820 shares worth $65.5M. The position accounts for 0.06% of the portfolio, ranked #275.

ClearBridge Investments first reported a position in PTGX in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • ClearBridge Investments held 621,820 shares of Protagonist Therapeutics worth $65.5M as of Q1 2026.
  • ClearBridge Investments bought 131,978 Protagonist Therapeutics shares in Q1 2026, an estimated $11.7M.
  • Protagonist Therapeutics made up 0.06% of ClearBridge Investments's portfolio in Q1 2026, its #275 holding.
  • ClearBridge Investments first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on ClearBridge Investments's 13F filing for Q1 2026, filed 13 May 2026.